What is the 13F Pro Quality Score for MGRX?

13F Pro ranks MANGOCEUTICALS, INC. (MGRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MGRX's current score at https://13fpro.ai/research/MGRX (free sign-up required for the full ranking).

Where does 13F Pro source MGRX data?

All MANGOCEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. MANGOCEUTICALS, INC. files with the SEC under CIK 1938046. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MGRX in?

MANGOCEUTICALS, INC. (MGRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MGRX research updated on 13F Pro?

MGRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MANGOCEUTICALS, INC.(MGRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1938046 MGRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MGRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MANGOCEUTICALS, INC. (MGRX), a Healthcare sector company. MGRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), MANGOCEUTICALS, INC. reports quarterly revenue of $67.9K, net income of $-3.4M, free cash flow of $-1.3M. Top institutional holders of MGRX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Ikarian Capital,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MGRX trades on the Nasdaq exchange and files with the SEC under CIK 1938046. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MANGOCEUTICALS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$67.9K

Net Income

Q1 2026

$-3.4M

Free Cash Flow

Q1 2026

$-1.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-15.8% YoY

$615.9KFY 2024

FY21 —FY23 $731.5KFY24 $615.9K

Net Income

+5.5% YoY

$-8.7MFY 2024

FY21 —FY23 $-9.2MFY24 $-8.7M

Operating Income

+13.5% YoY

$-8.0MFY 2024

FY21 —FY23 $-9.2MFY24 $-8.0M

EPS (Diluted)

-739.2% YoY

$-4.80FY 2024

FY21 —FY23 $-0.57FY24 $-4.80

Total Assets

+1362.8% YoY

$15.4MFY 2024

FY21 —FY23 $1.1MFY24 $15.4M

Op. Cash Flow

+30.5% YoY

$-4.9MFY 2024

FY21 —FY23 $-7.0MFY24 $-4.9M

Metric	FY 2024	FY 2023	FY 2021
Revenue	$615.9K -15.8%	$731.5K	—
Net Income	$-8.7M +5.5%	$-9.2M	—
Operating Income	$-8.0M +13.5%	$-9.2M	—
EPS (Diluted)	$-4.80 -739.2%	$-0.57	—
Total Assets	$15.4M +1362.8%	$1.1M	—
Operating Cash Flow	$-4.9M +30.5%	$-7.0M	—

AI Insight: MGRX Financial Trends

Pre-revenue biotech burning cash with no commercial traction and escalating operating losses through Q3 2025, though Q4 2025–Q1 2026 show modest stabilization.

• Operating losses peaked at $8M in Q3 2025, then improved to $0M (Q4 2025) and $3M loss (Q1 2026).

• Operating cash burn remained stable at ~$1–2M per quarter; no revenue generation across all eight quarters.

• Equity declined from $20M (Q1 2025 peak) to $13M (Q1 2026), eroding shareholder value despite fundraising.

⚠ Q3 2025 net loss of $8M was 2.7× the baseline quarterly burn; root cause and sustainability unclear.

⚠ Runway at current $1–3M quarterly burn is finite; no disclosed milestones or pipeline advances evident.

AI Insight: MGRX Ratio Trends

MGRX remains unprofitable across all return metrics, with ROE deteriorating sharply to -101.0% in Q1 2026 after a brief Q4 2025 stabilization.

• ROE swung from -72.9% in Q4 2025 to -101.0% in Q1 2026, signaling renewed earnings deterioration in the latest quarter.

• ROA and ROIC both declined to -94.2% and -92.8% respectively in Q1 2026, near their worst levels since Q3 2025.

• No positive operating or net profit margins visible across any period; company remains structurally unprofitable.

⚠ Q4 2025 ROIC at -9.7% was anomalously better than adjacent quarters; whether this reflects one-time gains or sustainable improvement unclear.

⚠ Debt-to-equity ratio absent from all periods; leverage position and balance sheet health cannot be assessed from this data.

Get alerted when MGRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MANGOCEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MGRX

GEODE CAPITAL MANAGEMENT, LLC
$70.0K194,482 sh
Ikarian Capital, LLC
$49.7K138,146 sh
VANGUARD CAPITAL MANAGEMENT LLC
$44.3K123,041 sh
JANE STREET GROUP, LLC
$26.2K72,746 sh
VANGUARD FIDUCIARY TRUST CO
$20.6K57,163 sh
BOOTHBAY FUND MANAGEMENT, LLC
$13.8K38,441 sh
NORTHERN TRUST CORP
$13.5K37,579 sh
Ackerman Capital Advisors, LLC
$12.4K34,500 sh
StoneX Group Inc.
$5.8K16,039 sh
XTX Topco Ltd
$4.7K13,142 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$70.0K	194,482
Ikarian Capital, LLC	$49.7K	138,146
VANGUARD CAPITAL MANAGEMENT LLC	$44.3K	123,041
JANE STREET GROUP, LLC	$26.2K	72,746
VANGUARD FIDUCIARY TRUST CO	$20.6K	57,163
BOOTHBAY FUND MANAGEMENT, LLC	$13.8K	38,441
NORTHERN TRUST CORP	$13.5K	37,579
Ackerman Capital Advisors, LLC	$12.4K	34,500
StoneX Group Inc.	$5.8K	16,039
XTX Topco Ltd	$4.7K	13,142

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MGRX on your watchlist

Track score changes the day MANGOCEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MGRX a good stock to buy?

13F Pro's AI-powered analysis of MANGOCEUTICALS, INC. (MGRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MGRX are available on the MGRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MGRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MGRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MANGOCEUTICALS, INC.'s investment landscape.